Patient Perception of Bladder Condition after Treatment with Solifenacin and Tolterodine in Overactive Bladder Patients

Patient Perception of Bladder Condition after Treatment with Solifenacin and Tolterodine in Overactive Bladder Patients

.

Bibliographic Details
Main Authors:	Tarun Pradhan, Jiba Nath Dhamala, Siddartha Kumar Yadav, Amit Deo
Format:	Article
Language:	English
Published:	Nepal Health Research Council 2023-03-01
Series:	Journal of Nepal Health Research Council
Online Access:	https://jnhrc.com.np/index.php/jnhrc/article/view/4366

Similar Items

Clinical and urodynamic effects of tolterodine in women with an overactive bladder
by: Chiu-Lin Wang, et al.
Published: (2013-09-01)

Tolterodine Tartrate Proniosomal Gel Transdermal Delivery for Overactive Bladder
by: Rajan Rajabalaya, et al.
Published: (2016-08-01)

Solifenacin versus posterior tibial nerve stimulation for overactive bladder in patients with multiple sclerosis
by: Nastaran Majdinasab, et al.
Published: (2023-02-01)

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK
by: Zalmai Hakimi, et al.
Published: (2018-01-01)

Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists
by: Mateusz Małkowski, et al.
Published: (2024-01-01)

Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database
by: Christopher R. Chapple, et al.
Published: (2016-12-01)

6 - Preliminary assessment of the efficacy and tolerability of solifenacin for the treatment of neurogenic overactive bladder in patients affected by multiple sclerosis
by: Eleonora Rosato, et al.
Published: (2023-06-01)

Comparison of micro-radiofrequency therapy and tolterodine for the treatment of newly diagnosed overactive bladder: A retrospective cohort study
by: Min Tang, et al.
Published: (2023-03-01)

Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin
by: Marloes J. Tijnagel, et al.
Published: (2017-04-01)

SAFETY AND EFFICACY OF THE PERONEAL ELECTRIC TRANSCUTANEOUS NEUROMODULATION (PERONEAL ETNM®) VERSUS SOLIFENACIN IN PATIENTS WITH OVERACTIVE BLADDER WET AND MIXED URINARY INCONTINENCE
by: J Krhut, et al.
Published: (2023-09-01)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
by: Mohammed A. Al-Ghazo, et al.
Published: (2011-03-01)

Re: Comparative Effectiveness of Combined Low- and Standart-Dose Trospium and Solifenacin for Moderate Overactive Bladder Symptoms in Elderly Men and Women
by: Kirill V. Kosilov, et al.
Published: (2015-03-01)

Clinical Efficacy of Solifenacin in the Management of Diabetes Mellitus-Associated Versus Idiopathic Overactive Bladder Symptoms: A Multicenter Prospective Study
by: Hoon Choi, et al.
Published: (2018-03-01)

Effect of electroacupuncture versus solifenacin for moderate and severe overactive bladder: a multi-centre, randomized controlled trial study protocol
by: Qian Wen, et al.
Published: (2020-07-01)

Effect of caffeine on bladder function in patients with overactive bladder symptoms
by: Supatra Lohsiriwat, et al.
Published: (2011-01-01)

MANAGEMENT OF PATIENTS WITH PARKINSON’S DISEASE AND AN OVERACTIVE BLADDER
by: E. S. Korshunova, et al.
Published: (2018-01-01)

Associations among Physician–Patient Communication, Patient Satisfaction, and Clinical Effectiveness of Overactive Bladder Medication: A Survey of Patients with Overactive Bladder
by: Naoko Izumi, et al.
Published: (2022-07-01)

Updates of Overactive Bladder in Pediatrics
by: Jisung Shim, et al.
Published: (2023-03-01)

OVERACTIVE BLADDER SYNDROME IN CHILDREN
by: E.L. Vishnevskiy
Published: (2007-01-01)

OVERACTIVE BLADDER SYNDROME IN CHILDREN
by: E.L. Vishnevskiy
Published: (2007-03-01)

The Experimental overactive bladder modelling
by: O. I. Iatsyna, et al.
Published: (2018-07-01)

Pharmacoeconomic feasibility of using Mirabegron in patients with overactive bladder
by: I. N. Dyakov, et al.
Published: (2021-04-01)

Oxybutynin and tolterodine for treatment of neurogenic detrusor overactivity: a pharmacoeconomic evaluation in the Brazilian context
by: Rodrigo Silva Suguino, et al.
Published: (2012-06-01)

Editorial Comment: Solifenacin treatment after intradetrusor injections with botulinum toxin in patients with neurogenic detrusor overactivity
by: Marcio Augusto Averbeck
Published: (2022-11-01)

Establishment of an overactive bladder model in mice
by: Tengfei Lv, et al.
Published: (2023-02-01)

Mirabegron in the Management of Overactive Bladder Syndrome
by: O'Kane M, et al.
Published: (2022-09-01)

Individualizing medical treatment of overactive bladder
by: Hann-Chorng Kuo
Published: (2018-01-01)

New in the diagnosis of overactive bladder (review)
by: F N Mahmedzhanova, et al.
Published: (2013-04-01)

OnabotulinumtoxinA for the treatment of overactive bladder
by: Cox L, et al.
Published: (2014-07-01)

The Urobiome and Its Role in Overactive Bladder
by: Sangrak Bae, et al.
Published: (2022-09-01)

Patients’ Preferences and Expectations in Overactive Bladder: A Systematic Review
by: Antonio Cicione, et al.
Published: (2023-01-01)

Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder
by: Shaw C, et al.
Published: (2023-01-01)

Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin
by: Tondalaya Gamble, et al.
Published: (2008-11-01)

Differences in the Urinary Microbiome of Patients with Overactive Bladder Syndrome with and without Detrusor Overactivity on Urodynamic Measurements
by: Aida Javan Balegh Marand, et al.
Published: (2023-05-01)

Increased Bladder Wall Thickness in Diabetic and Nondiabetic Women With Overactive Bladder
by: Hakkı Uzun, et al.
Published: (2013-06-01)

Mechanisms Underlying Overactive Bladder and Interstitial Cystitis/Painful Bladder Syndrome
by: Luke Grundy, et al.
Published: (2018-12-01)

Constitution and Validation of a New Symptom Assessment Tool for Overactive Bladder: Marmara Overactive Bladder Questionnaire (M-OBQ)
by: Tufan Tarcan, et al.
Published: (2014-11-01)

Assessment of bladder pressure and discomfort symptoms: How do overactive bladder differ from interstitial cystitis/bladder pain syndrome patients?
by: Angelíca Gousse, et al.
Published: (2023-03-01)

Quality of Life in Female Patients with Overactive Bladder after Botulinum Toxin Treatment
by: Agnieszka A. Licow-Kamińska, et al.
Published: (2023-12-01)

NMDAR in bladder smooth muscle is not a pharmacotherapy target for overactive bladder in mice
by: Xiang Xie, et al.
Published: (2021-07-01)